

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/126693 A1

(51) International Patent Classification:

C07D 401/10 (2006.01) *A61K 31/501* (2006.01)
C07D 401/14 (2006.01) *A61K 31/506* (2006.01)
A61K 31/444 (2006.01) *A61P 3/04* (2006.01)
A61K 31/497 (2006.01) *A61P 5/38* (2006.01)

(21) International Application Number:

PCT/US2020/064493

(22) International Filing Date:

11 December 2020 (11.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/949,854 18 December 2019 (18.12.2019) US

(71) Applicant: **CRINETICS PHARMACEUTICALS, INC.**

[US/US]; 10222 Barnes Canyon Road, Building #2, San Diego, California 92121 (US).

(72) **Inventors:** **HAN, Sangdon**; 10222 Barnes Canyon Road, Building #2, San Diego, California 92121 (US). **KIM, Sun Hee**; 10222 Barnes Canyon Road, Building #2, San Diego, California 92121 (US). **ZHU, Yunfei**; 10222 Barnes Canyon Road, Building #2, San Diego, California 92121 (US).

(74) **Agent:** **BAGULEY, Tyler D.**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF

(57) **Abstract:** Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

